Skip to main content

Heart Transplant clinical trials at University of California Health

10 in progress, 5 open to eligible people

Showing trials for
  • Allograft Dysfunction in Heart Transplant

    open to eligible people ages 18 years and up

    The investigators will evaluate for early evidence of cardiac allograft dysfunction by cardiac MRI and single cell sequencing to determine underlying molecular and macroscopic causes.

    at UCSD

  • MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation

    open to eligible people ages 18 years and up

    Cardiac rehabilitation is a medically recommended program for patients with certain heart conditions. It includes exercise training, health education, and counseling. Unfortunately, many patients do not participate in cardiac rehabilitation. Some find it challenging to attend the in-person sessions. This study aims to compare two methods of delivering cardiac rehabilitation: in-person and through telehealth. The investigators want to know if the effects of these two programs are alike and if certain individuals benefit more from one program over the other.

    at UCSF

  • XVIVO Heart Perfusion System (XHPS) With Supplemented XVIVO Heart Solution (SXHS)

    open to eligible people ages 18 years and up

    The purpose of this study is to evaluate if Non-Ischemic Heart Preservation (NIHP) of extended criteria donor hearts using the XVIVO Heart Preservation System (XHPS) is a safe and effective way to preserve and transport hearts for transplantation.

    at UCSD

  • Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation

    open to eligible people ages 18 years and up

    Demonstrate the impact of the Molecular Microscope Diagnostic System as the standard of care for heart transplant patients.

    at UCLA

  • Sponsor-Initiated OCS Heart Perfusion Registry

    open to all eligible people

    OHP-II Registry is a sponsor-initiated, multi-center, observational post-approval registry.

    at UCSF

  • Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score

    Sorry, in progress, not accepting new patients

    The TEAMMATE Trial will enroll 210 pediatric heart transplant patients from 25 centers at 6 months post-transplant and follow each patient for 2.5 years. Half of the participants will receive everolimus and low-dose tacrolimus and the other half will receive tacrolimus and mycophenolate mofetil. The trial will determine which treatment is better at reducing the cumulative risk of coronary artery vasculopathy, chronic kidney disease and biopsy proven-acute cellular rejection without an increase in graft loss due to all causes (e.g. infection, PTLD, antibody mediated rejection).

    at UCLA

  • Tocilizumab in Cardiac Transplantation

    Sorry, in progress, not accepting new patients

    The purpose of this research study is to see if a study drug called Tocilizumab will, when given with standard anti-rejection medicines, lead to better heart transplantation outcomes at 1 year after the transplant. Specifically, the investigators will evaluate whether taking tocilizumab leads to less rejection, less development of unwanted antibodies, and better heart function.

    at UCSD

  • Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation

    Sorry, in progress, not accepting new patients

    This is a prospective, multicenter observational, unblinded, longitudinal cohort study. Subjects will be enrolled into the study prior to or at the time of heart transplantation. All subjects will follow the center's standard of care surveillance schedule. Blood samples will be collected for Prospera testing at the time any surveillance or for-cause testing, which may include endomyocardial biopsy (EMB), echocardiography or other cardiac imaging studies, and/or molecular testing, is performed.

    at UCSD

  • Surveillance HeartCare® Outcomes Registry

    Sorry, in progress, not accepting new patients

    This is an observational registry to assess the clinical utility of surveillance using HeartCare testing services, in association with clinical care of heart transplant recipients.

    at UCLA UCSD UCSF

  • Trifecta-Heart cfDNA-MMDx Study

    Sorry, not currently recruiting here

    Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood transplant recipient and the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from heart transplants.

    at UCLA

Our lead scientists for Heart Transplant research studies include .

Last updated: